Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.

Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.
复制标题

DOI:
10.1016/j.vaccine.2014.07.031
复制
发表时间:
2014-09-03
期刊:
影响因子:
5.5
通讯作者:
Roy, Polly
Roy, Polly
中科院分区:
医学3区
文献类型:
--
作者:
Kanai, Yuta;van Rijn, Piet A.;Maris-Veldhuis, Mieke;Kaname, Yuki;Athmaram, T. N.;Roy, Polly

文献摘要

参考文献

被引文献

相似文献

非洲马瘟(AHS)是一种马疾病,易感马的死亡率高达90%。病原体AHS病毒(AHSV)由库蠓属物种传播。呼肠孤病毒科环状病毒属内的AHSV血清组由9种血清型组成,这些血清型不显示交叉中和或显示非常有限的交叉中和。在AHSV的七种结构蛋白(VP 1-VP 7)中,VP 2是血清型特异性蛋白,并且是中和抗体的主要靶点。在这份报告中,重组VP 2蛋白的所有9个血清型分别表达的杆状病毒表达系统和免疫豚鼠与单一的VP 2以及与VP 2蛋白的鸡尾酒的免疫原性进行了研究。通过50%空斑减少试验测量的同型半胱氨酸中和抗体显示不同程度的(从37到1365)不同VP 2蛋白的滴度。发现遗传相关的AHSV血清型的交叉中和抗体滴度较低。用含有等量的每种VP 2蛋白的VP 2混合物进行免疫也引发中和抗体,尽管对混合物中的每种血清型的滴度较低(4-117)。这项研究是开发AHS VP 2亚单位疫苗的第一步,我们的结果表明VP 2亚单位疫苗单独或在多血清型混合物中是可行的。
African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides. AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and the immunogenicity of each was studied by immunization of guinea pigs with single VP2 as well as with cocktails of VP2 proteins. Homologous neutralizing antibodies measured by 50% plaque reduction assay showed varying degrees (from 37 to 1365) of titers for different VP2 proteins. A low cross-neutralizing antibody titer was found for genetically related AHSV serotypes. Immunization with VP2 cocktails containing equal amounts of each of the VP2 proteins also triggered neutralizing antibodies albeit to lower titers (4-117) to each of the serotypes in the cocktail. This study is a first step to develop a VP2 subunit vaccine for AHS and our results indicate that VP2 subunit vaccines are feasible individually or in a multi-serotype cocktail.
DOI: 10.1016/j.pep.2013.07.005
发表时间: 2013-09-01
影响因子: 1.6
作者:
Kanai, Yuta;Athmaram, T. N.;Roy, Polly
通讯作者: Roy, Polly
DOI: 10.1016/j.vaccine.2014.04.036
发表时间: 2014-06-17
期刊: VACCINE
影响因子: 5.5
作者:
Alberca, Berta;Bachanek-Bankowska, Katarzyna;Cabana, Marta;Calvo-Pinilla, Eva;Viaplana, Elisenda;Frost, Lorraine;Gubbins, Simon;Urniza, Alicia;Mertens, Peter;Castillo-Olivares, Javier
通讯作者: Castillo-Olivares, Javier
DOI: 10.1016/j.vaccine.2009.05.044
发表时间: 2009-07-16
期刊: VACCINE
影响因子: 5.5
作者:
Guthrie, Alan J.;Quan, Melvyn;MacLachlan, N. James
通讯作者: MacLachlan, N. James
DOI: 10.1099/0022-1317-68-5-1233
发表时间: 1987-05-01
影响因子: 3.8
作者:
MATSUURA, Y;POSSEE, RD;BISHOP, DHL
通讯作者: BISHOP, DHL
DOI: 10.1099/0022-1317-77-9-2053
发表时间: 1996-09-01
影响因子: 3.8
作者:
Roy, P;Bishop, DHL;Erasmus, B
通讯作者: Erasmus, B